医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

More Than 400 Students of Zhangjiajie Daqiao Centre School Visited Jinchi Biotech Ltd.’s Giant Salamander Museum

2014年05月21日 AM02:00
このエントリーをはてなブックマークに追加


 

ZHANGJIAJIE, China

Jinchi Biotech Ltd., Since the Giant Salamander Museum opened to the public in 2010, it has played a significant role in the science education of Zhangjiajie local schools, and it was awarded national Science Education Base. On April 11, 2014, Zhangjiajie Giant Salamander Museum welcomed more than 400 students and teachers of Zhangjiajie Daqiao Centre School. During the guided tour the students were excited to learn a great deal of interesting knowledge about giant salamanders and in the quiz session after the tour they were able to answer most of the questions correctly. This has laid a solid foundation for the promotion of giant salamander knowledge as well as giant salamanders and environment protection among the student society.

On April 2014, a total of 31,713 tourists has visited the Giant Salamander Museum (excluding VIP and group tourists), which exhibited a 40.12% increase from April 2013.

ABOUT JINCHI

www.jc-biotech.com

Owning the world’s only Giant Salamander Museum, Jinchi Biotech Ltd. mainly specializes in the R&D of giant salamander related biotech products, with more than 40 skincare and health products under two product lines, namely SHINIQUE and ANDRIAS. With strong scientific research background and a comprehensive business model, Jinchi Biotech Ltd. values virtue and goodwill, commits to deliver quality products to consumers, and devotes to the health, beauty and biomedical industries.

Disclaimer

The statements contained herein are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements.

CONTACT

Jinchi Biotech Ltd.
Chan Luo, +86-731-8979-2661
ir@jc-biotech.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • BioVectra与Keryx Biopharmaceuticals签署枸橼酸铁扩产协议
  • Eternity Healthcare Inc. Enters into Share Exchange Agreement with Guizho Tongren Healthy China Biotechnology Co. Ltd.
  • Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease
  • Chi-Med Initiates Fruquintinib U.S. Clinical Trials
  • Orthocell Granted European Tendon Regeneration Patent